Zepbound Cost in Florida 2026: Cash Price, Insurance, Medicaid, and Compounded Options

What Does Zepbound Actually Cost in Florida in 2026?

The Eli Lilly wholesale acquisition cost (WAC) for Zepbound is $1,059 per month for all doses in 2026. Florida retail pharmacies, including major chains like CVS, Walgreens, and Publix Pharmacy, generally price at or near that WAC for cash-pay patients. No state-level Florida pricing law discounts this below the manufacturer's list.

That number is the starting point. What you actually pay depends on three factors: your insurance coverage, whether you qualify for the Lilly savings card, and whether compounded tirzepatide is a clinically appropriate and legal option for you.

Breaking Down the $1,059 Figure

Zepbound comes in six doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg single-dose autoinjectors. Eli Lilly set a single monthly list price across all dose strengths, which simplifies the math but does not soften the sticker shock for uninsured Floridians. The price reflects the drug's dual GIP and GLP-1 receptor agonist mechanism, the clinical data supporting it, and the current market structure for branded obesity medications.

How Florida Retail Pricing Compares Nationally

Florida does not have a state drug pricing transparency law that meaningfully caps retail WAC passthroughs, so Florida cash prices track closely to the national list. Patients in states with aggressive Medicaid supplemental rebate programs may see lower effective costs through public plans, but Florida Medicaid's exclusion of Zepbound for weight management removes that route entirely for most patients.

Florida Medicaid and Zepbound: What the Coverage Rules Say

Florida Medicaid does not cover Zepbound for chronic weight management as of 2026. The Florida Agency for Health Care Administration (AHCA) follows a restrictive preferred drug list for anti-obesity medications. Tirzepatide is covered under Florida Medicaid only when prescribed for type 2 diabetes under the brand name Mounjaro, not Zepbound. The FDA approved Mounjaro separately for glycemic control in adults with type 2 diabetes.

Why the Distinction Between Mounjaro and Zepbound Matters

Mounjaro and Zepbound contain the same active molecule: tirzepatide. The difference is the approved indication. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. Florida Medicaid covers Mounjaro for qualifying diabetic patients but has not extended that coverage to Zepbound for obesity alone. A patient who has both type 2 diabetes and obesity may access tirzepatide through the Mounjaro pathway on Florida Medicaid, but a patient whose sole indication is weight management cannot.

Florida Medicaid Managed Care Plans

Most Florida Medicaid enrollees are in managed care plans (Staywell, Molina, Simply Healthcare, and others) rather than fee-for-service Medicaid. Each plan maintains its own preferred drug list, but all are bound by AHCA guidance. None of the major Florida Medicaid managed care organizations covered Zepbound for weight management as of mid-2025, and no policy change has been announced for 2026. Patients should call their specific plan to confirm, because formulary updates do occur.

Commercial Insurance Coverage for Zepbound in Florida

Commercial insurance coverage for Zepbound in Florida is genuinely variable. Some large employer plans cover it; many do not. The key variables are whether the employer opted into anti-obesity medication (AOM) coverage and whether the specific plan formulary includes Zepbound.

Which Plan Types Are Most Likely to Cover It

Fully insured plans regulated by Florida's Office of Insurance Regulation follow each insurer's own formulary decisions. Florida state law does not mandate coverage of AOMs. Self-funded employer plans governed by ERISA are exempt from state mandates and make their own coverage decisions. Federal employee plans (FEHB) have added Zepbound coverage in some options starting in 2025. Medicare Part D plans are federally prohibited from covering drugs approved solely for weight loss, which means Medicare enrollees cannot access Zepbound through Part D unless they also have a covered comorbidity diagnosis pathway opened by future legislation.

What to Look for on Your Florida Insurance Plan

Before assuming coverage, request a formulary exception or prior authorization review. Insurers commonly require documentation of a BMI <30 or BMI <27 with at least one weight-related comorbidity, a record of a failed lifestyle intervention, and sometimes a step-therapy trial of a lower-cost AOM first. Florida Blue, Cigna, Aetna, and UnitedHealthcare each manage Zepbound differently across their Florida product lines, so a phone call to the member services number on your insurance card is the only way to get a definitive answer.

Typical Copay After Insurance

For patients whose commercial plans do cover Zepbound, copays typically range from $30 to $150 per month depending on tier placement and deductible status. Specialty-tier placement, which some plans use for Zepbound, can push the copay to $200 or more even after coverage kicks in.

The Eli Lilly Zepbound Savings Card: How It Works in Florida

Eli Lilly offers a savings card program for Zepbound that can reduce costs to as low as $25 per month for commercially insured patients who meet eligibility criteria. The program is managed through Lilly's patient services portal.

Eligibility Requirements

The savings card is available to patients who: have commercial insurance that covers Zepbound, are not enrolled in a federal or state government program (Medicare, Medicaid, TRICARE, VA), and are prescribed Zepbound by a licensed provider. Florida patients on Florida Medicaid or Medicare Part D do not qualify. The savings apply to the patient's cost-share after insurance, not to the full list price.

The Lilly Self-Pay Option

Lilly also offers a separate self-pay program for uninsured patients or those whose insurance does not cover Zepbound. As of 2026, this has been structured as a reduced cash price of approximately $399 to $550 per month depending on dose, accessed through participating pharmacies. Patients should verify the current self-pay price directly with Lilly's access support line or at the Zepbound website, because these programs adjust without notice.

How to Activate the Card in Florida

Activation requires a valid prescription, a U.S. Address (Florida qualifies), and online or phone enrollment through Lilly's program. Most major Florida pharmacy chains accept the savings card at point of sale. Publix Pharmacy, Walgreens, CVS, and Walmart Pharmacy in Florida have all been confirmed participants, though patients should verify at their specific location.

Compounded Tirzepatide in Florida: Legal Status and Pricing

Compounded tirzepatide is legal in Florida when dispensed by a licensed 503A compounding pharmacy operating under Florida Board of Pharmacy oversight. The legal field here is more nuanced than it appears in most online discussions, and the regulatory situation shifted significantly in 2024 and 2025.

The FDA Shortage Pathway and Its Current Status

The FDA placed tirzepatide on its drug shortage list in 2022, which opened the door for 503A and 503B compounding facilities to produce tirzepatide-based compounds legally under federal law. The FDA removed tirzepatide from the shortage list in early 2025, triggering a compliance deadline for compounders to wind down production of essentially copies of FDA-approved finished drug products. The FDA extended enforcement discretion timelines, but the core rule is now clear: compounded tirzepatide that is essentially a copy of Zepbound or Mounjaro cannot be produced for general use by 503A pharmacies once the shortage resolution is fully enforced.

What 503A Florida Pharmacies Can Still Legally Do

A Florida 503A pharmacy can still compound tirzepatide for an individual patient if there is a documented clinical need for a variation that the commercially available product cannot meet, such as a different concentration, an excipient substitution for an allergy, or a different delivery vehicle. This is a patient-specific prescription with a documented clinical rationale, not a general inventory product. Patients ordering compounded tirzepatide in Florida in 2026 should confirm that the pharmacy is a Florida-licensed 503A facility, that a licensed prescriber has documented the individualized clinical need, and that the pharmacy is not marketing a product that is essentially identical to Zepbound's approved formulation.

Compounded Tirzepatide Pricing in Florida

When legally available, compounded tirzepatide from Florida 503A pharmacies has been priced around $249 per month for standard weekly injection doses. This is roughly 76% less than the Eli Lilly list price. The lower cost reflects the absence of branded drug markups, but patients should understand that compounded drugs are not FDA-approved for safety and efficacy and are not interchangeable with Zepbound in a regulatory sense. The FDA has issued guidance on this distinction.

Telehealth and Zepbound Prescriptions in Florida

Zepbound can be prescribed via telehealth in Florida. State law permits controlled substance and non-controlled prescription drug prescribing via synchronous audio-video telehealth visits with a licensed Florida provider. Tirzepatide is not a controlled substance, so it does not require an in-person visit under either federal DEA rules or Florida statutes.

What a Florida Telehealth Visit for Zepbound Looks Like

A qualifying telehealth visit for Zepbound in Florida typically includes a review of BMI, weight-related comorbidities, medication history, and contraindications. The FDA label for Zepbound requires a BMI of 30 or greater, or 27 or greater with at least one weight-related condition such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease. The full prescribing information is available through the FDA.

Most Florida telehealth platforms for obesity medicine will also order baseline labs (fasting glucose, HbA1c, lipid panel, thyroid function) before prescribing. The prescription is then sent to a Florida pharmacy of the patient's choice or to a mail-order pharmacy licensed in Florida.

Telehealth Platform Costs in Florida

Telehealth visits themselves carry a separate cost. Platforms serving Florida patients charge anywhere from $0 (if the visit is covered by insurance) to $199 for an initial obesity medicine consultation. Monthly or quarterly follow-up visits typically run $50 to $99 per session when not covered by insurance. These costs are separate from and in addition to the medication cost.

The Clinical Case for Tirzepatide: Why the Price Exists

The pricing of Zepbound reflects a drug with genuinely strong clinical outcomes. In SURMOUNT-1 (N=2,539, 72 weeks), participants randomized to tirzepatide 15 mg achieved a mean body weight reduction of 22.5% compared to 2.4% with placebo [P<0.001]. The full trial results were published in the New England Journal of Medicine in 2022. At 10 mg, mean weight loss was 21.4%. At 5 mg, it was 16.0%. All three doses significantly outperformed placebo at each time point measured.

SURMOUNT-1 Subgroup Data Relevant to Florida Patients

Approximately 14% of SURMOUNT-1 participants had pre-diabetes at baseline. Among those patients, 95.3% of participants on tirzepatide 15 mg had reverted to normoglycemia by week 72, compared to 61.9% on placebo. Given Florida's high rates of obesity and pre-diabetes (the CDC estimates that roughly 11.5% of Florida adults have diagnosed diabetes and a much larger proportion have pre-diabetes), these numbers carry particular relevance for Florida prescribers. CDC data on Florida diabetes prevalence is available here.

What the Endocrine Society Says About Obesity Pharmacotherapy

The 2023 Endocrine Society Clinical Practice Guideline on Pharmacological Management of Obesity states: "We recommend pharmacological therapy for patients with obesity (BMI >=30 kg/m2) or for patients with overweight (BMI 27-29.9 kg/m2) who have weight-related complications when lifestyle intervention alone is insufficient." This aligns directly with Zepbound's FDA-approved indication and supports the clinical rationale Florida providers use when prescribing it. The full guideline is available through the Endocrine Society.

Strategies for Reducing Zepbound Costs in Florida

Several concrete pathways exist for Florida patients trying to reduce their monthly out-of-pocket spend on Zepbound.

Prior Authorization and Appeals

If your Florida commercial insurer denies Zepbound coverage, file a formal appeal. Florida law requires insurers to provide an internal appeal process and an external independent review option. Appeals that include a letter of medical necessity from your prescriber, documentation of failed prior lifestyle interventions, and a clear BMI with comorbidity documentation succeed more often than denials that go unchallenged.

Patient Assistance Programs

Lilly's LillyAnswers program provides Zepbound at low or no cost to uninsured or underinsured patients who meet income thresholds (generally at or below 400% of the federal poverty level). Enrollment is through Lilly's patient assistance team and requires documentation of income and insurance status. Processing typically takes two to four weeks.

GoodRx and Pharmacy Discount Cards

GoodRx and similar pharmacy discount programs do not meaningfully discount Zepbound because the drug has no significant generic competition and Lilly's WAC is set uniformly. Discount cards typically return a price within a few dollars of the full list price for branded GLP-1 medications. These programs are more useful for generic medications.

Switching Between Dose Strengths Strategically

Because Eli Lilly prices all Zepbound doses at the same WAC, patients who have reached their maintenance dose at a lower strength (for example, 5 mg or 7.5 mg) are paying the same as patients on 15 mg. There is no financial advantage to staying at a lower dose from a cost perspective, but there may be a tolerability advantage that a prescriber might consider.

What Florida Patients Should Ask Their Provider Before Starting

Before filling a first Zepbound prescription in Florida, patients should have direct conversations with their prescriber about several practical matters.

First, confirm that a prior authorization will be submitted if you have commercial insurance, and ask for a realistic timeline. Prior authorization turnarounds in Florida run five to fifteen business days for most commercial plans.

Second, ask whether your provider has experience prescribing Zepbound or other GLP-1/GIP agonists and whether their practice can support the follow-up visit schedule. Zepbound dose escalation follows a structured protocol: patients typically start at 2.5 mg weekly for four weeks, then advance to 5 mg, with further dose increases every four weeks as tolerated up to 10 or 15 mg.

Third, ask about thyroid risk. Zepbound carries an FDA boxed warning for thyroid C-cell tumors based on rodent studies. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not take Zepbound. Florida providers prescribing via telehealth are required to document this contraindication screening in the visit record.

The Florida Department of Health does not maintain a state-specific registry for Zepbound prescriptions, but the FDA's MedWatch program accepts voluntary adverse event reports from Florida patients and providers. MedWatch reporting is available here.